SCHEMBL5214939

SCHEMBL5214939

CN(Cc1cccc(O)c1)c1cnc(-c2ccccc2)c(-c2ccccc2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.54
SKP1 P63208 2/20 0.54
SKP2 Q13309 2/20 0.54
HSD17B1 P14061 11/20 0.46
HSD17B2 P37059 11/20 0.46
CNR1 P21554 1/20 0.45
ERAP1 Q9NZ08 1/20 0.44
CSF1R P07333 1/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
ADORA1 P30542 1/20 0.40
NR1I2 O75469 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
DRD1 P21728 1/20 0.39
TBXA2R P21731 1/20 0.39
AGTR1 P30556 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219541 0.88 CKS1B (0.51) CKS1BSKP1SKP2ESR1ESR2
SCHEMBL30725788 0.85 CKS1B (0.54) CKS1BSKP1SKP2CNR1MAPT
SCHEMBL28707159 0.85 CKS1B (0.54) CKS1BSKP1SKP2CNR1MAPT
SCHEMBL16451103 0.83 CKS1B (0.51) CKS1BSKP1SKP2HSD17B2CSF1R
SCHEMBL5214444 0.81 CKS1B (0.48) CKS1BSKP1SKP2CNR1SMN1; SMN2
SCHEMBL28707153 0.81 CKS1B (0.57) CKS1BSKP1SKP2CNR1MAPT
SCHEMBL30725783 0.81 CNR1 (0.62) CKS1BSKP1SKP2CNR1MAPT
SCHEMBL28707155 0.81 CNR1 (0.62) CKS1BSKP1SKP2CNR1MAPT
SCHEMBL30725780 0.81 CKS1B (0.57) CKS1BSKP1SKP2CNR1MAPT
SCHEMBL5213601 0.80 CKS1B (0.48) CKS1BSKP1SKP2CNR1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7205302-B2 Anticoagulants; antilipemic agents; cardiovascular disorders NIPPON SHINYAKU CO., LTD. (JP) 2007-04-17 US disclosed
EP-1400518-B1 HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES NIPPON SHINYAKU CO LTD (JP) 2007-01-17 EP disclosed
US-20040102436-A1 Heterocyclic compound derivatives and medicines NIPPON SHINYAKU CO., LTD. (JP) 2004-05-27 US disclosed
EP-1400518-A1 HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES Nippon Shinyaku Co., Ltd. (JP) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102436-A1 Heterocyclic compound derivatives and medicines CNR2, CNR1, GPR55 CKS1B 858/4885SKP1 2426/4885SKP2 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.